How to Cite
Abstract
The purpose of the study is to assess the effectiveness and toxicity of the treatment of prostate cancer (PCa) with combined radiation therapy (CRT), where high dose rate brachytherapy (HDR-BT) "boost".
Materials and methods: CRT was carried out in 98 patients of high-risk and extremely high-risk PCa. External part of treatment (conformal external radiation therapy) provided total dose 46-50 Gy with a single focal dose (SFD) 2 Gy to the prostate gland (PG), seminal vesicles and regional lymphatic zones. Two regimes of "boost" to the PG and seminal vesicles were used: in the first group – two fractions of 10 Gy (81 patients), in the second - 15 Gy (17 patients).
Results: median follow-up equals: I group - 57.5 months, II group - 55.2. Three- and five-year survival without biochemical progression in group I - 75.4% and 69.0%, II group - 76.4% and 52.9%, respectively. Similar indicators regardless of the CRT regime in groups of different risk of relapse were equal: high risk - 84.6% and 75.9%, extremely high risk - 69.4% and 60.7%, respectively (p=0.05).
There were no late radiation genitourinary and gastrointestinal complications of 4-5 degrees. The most significant variants of late disorders were the formation of urethra stricture (one patient of the I group) and stenosis of the rectum (one patient of the II group). Late genitourinary radiation toxicity (L-GURT) was mainly represented by changes that can be characterized as 1 degree (RTOG/CTCAE): I group - from 40.6% to 53.2%, II - 18.8% to 35.3%.
Conclusions: the studied CRT regimes showed perfectly acceptable survival rates with no signs of biochemical progression and radiation toxicity during the five-year period of follow-up.
References
Tosco L., Briganti A., D'amico A.V. et al. Systematic review of systemic therapies and therapeutic combinations with local treatments for high-risk localized prostate cancer. Eur Urol. 2019;75:44-60. doi: 10.1038/s41585-018-0017-x.
Zattoni F., Morlacco A., Matrone F. et al. Multimodal treatment for high-risk locally-advanced prostate cancer following radical prostatectomy and extended lymphadenectomy. Minerva Urol Nefrol. 2019;71:508-15. doi: 10.23736/S0393-2249.19.03388-5.
Heidenreich A., Fossati N., Pfister D. et al. Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases. Eur Urol Oncol. 2018;1(1):46-53. doi: 10.1016/j.euo.2018.03.002.
Kishan A.U., Shaikh T., Wang P.C. et al. Clinical outcomes for patients with Gleason score 9-10 рrostate adenocarcinoma treated with radiotherapy or radical prostatectomy: a multiinstitutional comparative analysis. Eur Urol. 2017;71(5):766-773. doi: 10.1016/j.eururo.2016.06.046.
Sandler K.A., Cook R.R., Ciezki J.P. et al. Clinical outcomes for patients with Gleason score 10 prostate adenocarcinoma: results from a multi-institutional consortium study. Int J Radiat Oncol Biol Phys. 2018;101(4):883-888. doi: 10.1016/j.ijrobp.2018.03.060.
Kishan A.U., Cook R.R., Ciezki J.P. et al. Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9-10 prostate cancer. JAMA. 2018;319(9):896-905. doi: 10.1001/jama.2018.0587.
Tilki D., Chen M.H., Wu J. et al. Surgery vs radiotherapy in the management of biopsy Gleason score 9-10 prostate cancer and the risk of mortality. JAMA Oncol. 2019;5(2):213-220. doi: 10.1001/jamaoncol.2018.4836.
Muralidhar V., Mahal B.A., Butler S. et al. Combined external beam radiation therapy and brachytherapy versus radical prostatectomy with adjuvant radiation therapy for Gleason 9-10 prostate cancer. J Urol. 2019;202(5):973-978. doi: 10.1097/JU.0000000000000352.
Lawton C.A., Michalski J., El-Naqa I. et al. RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74 (2): 383-387. doi: 10.1016/j.ijrobp.2008.08.002.
Новиков Р.В. Высокодозная брахитерапия рака предстательной железы. Медицинский вестник МВ. 2014;6:61-65 [Novikov R.V. High-dose brachytherapy of prostate cancer. MIA medical bulletin. 2014;6:61-65 (In Russ.)].
Новиков С.Н., Канаев С.В., Новиков Р.В. и др. Высокодозная брахитерапия рака предстательной железы в режиме реального времени с использованием источника 192-Ir (особенности дозиметрического планирования). Вопросы онкологии. 2015;61(1):130-6 [Novikov S.N., Kanaev S.V., Novikov R.V. et al. High-dose brachytherapy for prostate cancer in real time using 192-IR (specifics of dosimetric planning). Vopr Onkol. 2015;61(1):130-6 (In Russ.)].
Новиков С.Н., Канаев С.В., Новиков Р.В. и др. Клинический опыт использования брахитерапии источниками высокой мощности дозы для монотерапии больных раком предстательной железы. Вопросы онкологии. 2018;3:366-73 [Novikov S.N., Kanaev S.V., Novikov R.V. et al. Clinical experience of using brachytherapy with high dose rate sources for monotherapy in prostate cancer patients Vopr Onkol. 2018; 3: 366-373. doi.org/10.37469/0507-3758-2018-64-3-366-373 (In Russ.)].
Hoskin P., Colombo A., Henry A. et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: аn update. Radiother Oncol. 2013; 107: 325-332. doi: 10.1016/j.radonc.2013.05.002.
Новиков С.Н., Канаев С.В., Баянкин С.Н. и др. Рекомендации по лечению рака предстательной железы с помощью высокомощностной внутритканевой лучевой терапии (брахитерапии) Экспертное совещание, 17 ноября 2016, Москва. Экспериментальная и клиническая урология. 2017; 3:10-23 [Novikov S.N., Oshchepkov V.N., Kanaev S.V. et al. Guidelines for prostate cancer HDR-brachytherapy treatment. Expert meeting 17th November 2016, Moscow. Clinical and experimental urology. 2017; 3: 10-23 (In Russ.)].
Withers H.R., Thames Jr H.D., Peters L.J. A new isoeffect curve for change in dose per fraction. Radiother Oncol. 1983; 1(2): 187-191. doi: 10.1016/s0167-8140(83)80021-8.
Vogelius I.R., Bentzen S.M. Dose response and fractionation sensitivity of prostate cancer after external beam radiation therapy: a meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys. 2018;100(4):858-865. doi: 10.1016/j.ijrobp.2017.12.011.
Rosen R.C., Cappelleri J.C., Smith M.D. et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11(6):319-326. doi: 10.1038/sj.ijir.3900472.
Mohler J., Bahnson R.R., Boston B. et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8(2):162-200. doi: 10.6004/jnccn.2010.0012.
Roach M. 3rd., Hanks G., Jr. Thames H. et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65(4):965-974. doi: 10.1016/j.ijrobp.2006.04.029.
Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341-1346. doi: 10.1016/0360-3016(95)00060-C.
Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 / U.S. department of health and human services National Institutes of Health National Cancer Institute (2009).
Tharmalingam H., Tsang Y., Choudhury A. et al. External beam radiotherapy (EBRT) and high-dose rate (HDR) brachytherapy for intermediate and high-risk prostate cancer: the impact of EBRT volume. Int J Radiat Oncol Biol Phys. 2020;106(3):525-533. doi: 10.1016/j.ijrobp.2019.09.044.
Roach M., Marquez C., Yuo H.S. et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;28(1):33-37. doi: 10.1016/0360-3016(94)90138-4.
Zaorsky N.G., Den R.B., Doyle L.A. et al. Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer. Expert Rev Med Devices. 2013;10(6):751-63. doi: 10.1586/17434440.2013.841347.
Spratt D.E., Zumsteg Z.S., Ghadjar P. et al. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. BJU Int. 2014;114(3): 360-367. doi: 10.1111/bju.12514.
Morton G.C. High-dose-rate brachytherapy boost for prostate cancer: rationale and technique. J Contemp Brachyther. 2014;6(3):323-330. doi: 10.5114/jcb.2014.45759.
Liss A.L., Abu-Isa E.I., Jawad M.S. et al. Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: the impact of Gleason pattern 5. Brachytherapy. 2015;14(4):502-510. doi: 10.1016/j.brachy.2015.02.389.
Hoskin P.J., Rojas A.M., Bownes P.J. et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012;103(2):217-222. doi: 10.1016/j.radonc.2012.01.007.
Morris W.J., Tyldesley S., Rodda S. et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate сancer. Int J Radiat Oncol Biol Phys. 2017;98(2):275-285. doi: 10.1016/j.ijrobp.2016.11.026.
Sathya J.R., Davis I.R., Julian J.A. et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol. 2005;23(6):1192-1199. doi: 10.1200/JCO.2005.06.154.
Marshall R.A., Buckstein M., Stone N.N., Stock R. Treatment outcomes and morbidity following definitive brachytherapy with or without external beam radiation for the treatment of localized prostate cancer: 20-year experience at Mount Sinai Medical Center. Urol Oncol. 2014;32: 38. e1-7. doi: 10.1016/j.urolonc.2013.03.004.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2020